Every Form 4 that Vericel (VCEL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VCEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VCEL filings page.
Vericel Corp director Kevin F. McLaughlin exercised 7,000 stock options on August 12, 2026 at an exercise price of $13.05 per share, receiving 7,000 common shares. On the same date he sold 7,000 common shares at $44.53 per share in an automatic sale under a Rule 10b5-1 trading plan adopted on May 12, 2025. The exercised options were part of a grant originally covering 17,500 shares that vested in monthly installments.
Vericel Corp Chief Operating Officer Michael Halpin exercised stock options to acquire 10,000 shares of common stock at an exercise price of $16.66 per share, then sold 10,000 shares at $46.84 per share on August 3, 2026.
The options exercised are part of a grant originally covering 76,250 shares that vested quarterly beginning May 6, 2019, with 26,250 options reported remaining outstanding. The sale was executed automatically under a Rule 10b5-1 trading plan adopted on December 2, 2025, and Halpin’s direct holdings include shares acquired under Vericel’s 2015 Employee Stock Purchase Plan.
Vericel Corp Principal Accounting Officer Jonathan Siegal exercised stock options covering 4,500 shares of common stock on July 30, 2026 at exercise prices of $34.90 and $29.82 per share, then sold 4,500 shares at $48.90 per share under an automatic Rule 10b5-1 trading plan adopted on December 10, 2025.
Vericel Corp’s Principal Accounting Officer Jonathan Siegal reported a same-day option exercise and share sale. On June 26, 2026, he exercised 2,500 stock options at $29.82 per share and sold a total of 2,732 common shares at $44.90 per share in open-market transactions.
Following these trades, he holds 886 common shares directly and 6,500 stock options that remain outstanding and exercisable through February 17, 2033. The filing notes the sales were made under a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance.
Vericel Corp’s Chief Financial Officer, Mara Joseph Anthony Jr., reported an open-market sale of 5,000 shares of common stock. The transaction took place on June 26, 2026 at a price of $44.75 per share. Following this sale, he directly holds 16,009 shares of Vericel common stock.
The filing notes that the sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025, indicating it was scheduled in advance rather than timed discretionarily. The reported holdings include shares acquired through Vericel’s 2015 Employee Stock Purchase Plan under Rule 16b-3 exemptions.
Vericel Corp’s Chief Medical Officer, Jonathan Mark Hopper, reported an exercise-and-sell transaction in company stock. On June 26, 2026, he exercised stock options to acquire 10,000 shares of common stock at $29.82 per share and sold 10,000 shares in open-market trades at $45.00 per share in two 5,000-share blocks.
After these transactions, Hopper directly holds 75,753 shares of Vericel common stock and 25,000 remaining stock options with a $29.82 exercise price expiring on February 17, 2033. The sales were carried out under an automatic Rule 10b5-1 trading plan adopted on May 30, 2025, indicating they were pre-scheduled rather than discretionary market-timing trades.
Vericel Corp's Chief Legal Officer Sean C. Flynn exercised stock options and sold shares in a planned transaction. On June 26, 2026, he exercised options to acquire 15,000 shares of common stock at $16.25 per share, then sold 15,000 shares in an open-market transaction at an average price of $45.64 per share. The sales were made under an automatic Rule 10b5-1 trading plan adopted on December 2, 2025. After these transactions, he directly held 1,647 shares of Vericel common stock.
Vericel Corp Chief Operating Officer Michael Halpin reported an exercise-and-sale transaction in company stock. On June 18, 2026, he exercised options to acquire 10,000 shares of common stock at $16.66 per share and then sold 10,000 shares in an open-market transaction at $40.24 per share.
The filing notes that the sales were executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025, indicating the timing was set in advance. Following these transactions, Halpin directly holds 16,248 shares of Vericel common stock.
Vericel Corp Chief Legal Officer Sean C. Flynn exercised options to acquire 15,000 shares of common stock at $16.25 per share and, on the same day, sold 15,000 shares at an average price of $40.21 per share. The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025, indicating it was scheduled in advance. After these transactions, Flynn holds 1,647 common shares directly and 70,000 stock options exercisable at $16.25 per share that are scheduled to expire on November 4, 2029.
Vericel Corp Chief Medical Officer Jonathan Mark Hopper exercised stock options and sold shares in a coordinated transaction. He exercised options for 4,375 shares of common stock at $16.66 per share, then sold 4,375 shares at $35.00 per share the same day.
After these transactions, he directly holds 75,753 shares of Vericel common stock and retains 1,625 stock options exercisable at $16.66 per share, expiring on February 6, 2029. The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on May 30, 2025.
Vericel Corp director Kevin F. McLaughlin reported option exercises and related stock sales in Vericel common stock. On May 13, 2026, he exercised stock options to acquire a total of 7,000 shares of common stock, including 3,500 shares at an exercise price of $13.05 per share and 3,500 shares at $2.63 per share. On the same date, he sold 7,000 shares in open‑market transactions at prices of $32.82 and $32.83 per share. After these transactions, McLaughlin directly held 18,300 shares of Vericel common stock. The filing notes that the sales were automatic transactions executed under a Rule 10b5-1 trading plan adopted on May 12, 2025.
Vericel Corp director Paul K. Wotton sold 10,000 shares of Common Stock in open-market transactions. On May 11, 2026, he reported selling 7,500 shares at $32.64 per share and 2,500 shares at $33.05 per share. These are discretionary, open-market sales of existing shares.
Vericel Corp’s Chief Financial Officer, Mara Joseph Anthony Jr, completed an automatic open-market sale of 5,000 shares of common stock at $40.50 per share. The transaction occurred on May 7, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025.
Following the sale, the CFO continues to hold 21,009 Vericel shares directly, including shares previously acquired through the company’s 2015 Employee Stock Purchase Plan. The filing reflects a planned, programmatic sale rather than a discretionary one-time trade.
Vericel Corp’s Principal Accounting Officer Jonathan Siegal reported open-market sales of company common stock. On May 6, 2026, he sold 3,433 shares at $38.00 per share. On May 7, 2026, he sold an additional 1,422 shares at $40.50 per share.
The Form 4 states these transactions were made under an automatic Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were pre-arranged. After these sales, Siegal directly holds 1,118 shares of Vericel common stock, some of which were acquired through the company’s 2015 Employee Stock Purchase Plan.
Vericel Corp director Kevin F. McLaughlin reported compensation-related equity activity. He exercised 3,200 previously granted Restricted Stock Units (RSUs) into 3,200 shares of common stock, bringing his direct common stock holdings to 18,300 shares after the transactions.
On the same date, he received new awards of 3,200 RSUs and stock options for 8,000 shares of common stock at an exercise price of $33.43 per share. The new RSUs vest 100% on the earlier of April 29, 2027, or the first Annual Meeting of Stockholders following April 29, 2026, while the options vest over one year in equal monthly increments, contingent on continued service.
Vericel Corp director Alan L. Rubino increased his equity-based holdings through routine compensation awards and vesting. He acquired 3,200 shares of common stock via the vesting and conversion of previously granted Restricted Stock Units (RSUs), bringing his direct common stock holdings to 64,194 shares.
He also received a new grant of 3,200 RSUs, each representing a contingent right to one Vericel common share, which vest 100% on the earlier of April 29, 2027, or the first Annual Meeting of Stockholders following April 29, 2026. In addition, he was granted stock options for 8,000 shares at an exercise price of $33.43 per share, vesting in equal monthly increments over one year and expiring on April 29, 2036. These transactions reflect equity compensation and do not include any open-market purchases or sales.
Vericel Corp director Heidi Hagen reported routine equity compensation activity. She exercised 3,200 Restricted Stock Units into 3,200 shares of common stock, bringing her direct common stock holdings to 35,050 shares. She also received a new grant of 3,200 RSUs that vest 100% on the earlier of April 29, 2027 or the first Annual Meeting of Stockholders following April 29, 2026. In addition, she was granted stock options for 8,000 shares at an exercise price of $33.43 per share, vesting in equal monthly increments over one year and expiring on April 29, 2036. All transactions reflect awards and exercises rather than open‑market buying or selling.
Vericel Corp director Paul K. Wotton reported equity compensation activity rather than open-market trading. He exercised or converted 3,200 shares of Common Stock, bringing his direct holdings to 28,802 shares. The filing shows net share acquisitions only, with no reported sales.
Wotton also received new awards: 3,200 Restricted Stock Units and 8,000 stock options with a conversion or exercise price of $33.43 per share, expiring on April 29, 2036. The options vest over one year in equal monthly increments, while the RSUs vest 100% on the earlier of April 29, 2027 or the first annual stockholders meeting after April 29, 2026. Certain RSUs were deferred into Phantom Stock units under Vericel’s Deferred Compensation Plan and will be settled in shares of Common Stock at Wotton’s elected distribution date.
Vericel Corp director Lisa Wright reported equity compensation and a deferral election, with no open-market buying or selling. She exercised 3,200 Restricted Stock Units (RSUs) into an equal number of Phantom Stock units under Vericel’s Deferred Compensation Plan, and holds 15,851 shares of common stock afterward.
Wright also received a new grant of 3,200 RSUs, each representing one share of common stock, which vest 100% on the earlier of April 30, 2026, or the first Annual Meeting of Stockholders after April 30, 2025. In addition, she was granted stock options for 8,000 shares at an exercise price of $33.43, vesting in equal monthly increments over one year and expiring on April 29, 2036.
Vericel Corp director Robert L. Zerbe, M.D. reported equity compensation activity with no open-market buying or selling. On April 29, 2026, 3,200 Restricted Stock Units (RSUs) vested and were exercised into 3,200 shares of Vericel common stock, bringing his direct common stock holdings to 32,995 shares.
On the same date, he received new equity awards: a grant of 3,200 RSUs, each representing a contingent right to one share of common stock, that vest 100% on the earlier of April 29, 2027 or the first Annual Meeting of Stockholders following April 29, 2026, and a grant of stock options for 8,000 shares of common stock at an exercise price of $33.43 per share, vesting monthly over one year and expiring on April 29, 2036.
Vericel Corp Chief Medical Officer Jonathan Mark Hopper exercised and sold a small block of shares in a pre-planned transaction. On April 2, 2026 he exercised stock options for 3,472 shares of common stock at $10.95 per share and sold the same 3,472 shares at $35.00 per share under an automatic Rule 10b5-1 trading plan. After these transactions, he directly holds 75,556 Vericel common shares and 9,132 stock options that are exercisable at $10.95 per share and expire on August 20, 2028.
Vericel Corp director Alan L. Rubino exercised stock options to acquire 15,000 shares of common stock at $2.76 per share and chose to hold all of these shares. These options were originally granted on May 4, 2016 and would otherwise have expired on May 4, 2026. Following the exercise, Rubino directly owns 60,994 shares of Vericel common stock, and the exercised option grant has been fully used with no remaining derivative position from this award.
Vericel director Heidi Hagen exercised stock options to acquire 15,000 shares of common stock at an exercise price of $2.76 per share, then sold the same 15,000 shares at $32.41 per share on March 23, 2026.
The sale was carried out automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 14, 2024. These options were originally granted on May 4, 2016 and would have expired on May 4, 2026 if not exercised. Following the transactions, Hagen holds 31,850 shares of Vericel common stock directly.
Vericel Corp’s Chief Legal Officer Sean C. Flynn exercised options for 15,000 shares and sold a total of 21,421 common shares of VCEL on March 2, 2026. The sales, executed at prices around $34.75 and $35.36, were made under an automatic Rule 10b5-1 trading plan adopted on December 2, 2025. Following these transactions, Flynn directly held 1,262 common shares and 85,000 option-based rights.
Vericel Corp's Chief Operating Officer, Michael Halpin, sold 10,305 shares of common stock in an open-market transaction at $35.30 per share on March 2, 2026. The sale was executed automatically under a Rule 10b5-1 trading plan he adopted on December 2, 2025, leaving him with 16,080 directly owned shares.
Vericel Corp President and CEO Dominick Colangelo reported equity award vesting and related share movements. On February 24, 2026, he acquired a total of 36,500 shares of common stock through the exercise or conversion of restricted stock units, with a portion converted into phantom stock units and deferred under Vericel’s Deferred Compensation Plan. The company withheld 8,824 shares of common stock at a fair market value of $38.09 per share to cover tax obligations tied to the vesting. After these transactions, Colangelo directly owned 312,446 shares of Vericel common stock.
Vericel Corp Chief Medical Officer Jonathan Mark Hopper reported multiple equity compensation transactions tied to restricted stock units (RSUs). On the transaction date, several RSU awards vested and were converted to common stock, and some RSUs were deferred into phantom stock under Vericel’s Deferred Compensation Plan. The company withheld 1,335 and 636 shares of common stock to satisfy tax obligations at fair market values of $38.09 and $38.25 per share. Following these transactions, Hopper directly owned 75,556 shares of Vericel common stock.
Vericel Corporation’s Principal Accounting Officer, Jonathan Siegal, reported equity award activity involving restricted stock units (RSUs) and common stock. On February 24, 2026, he acquired 1,540 and 1,875 shares of common stock upon vesting of previously granted RSUs.
To cover tax obligations from these vestings, 627 and 738 shares of common stock were withheld by the company at fair market values of $38.09 and $38.25 per share. Following these transactions, Siegal directly owned 5,847 shares of Vericel common stock, along with remaining unvested RSUs scheduled to vest in future years.
Vericel Corp’s Chief Financial Officer Mara Joseph Anthony Jr reported equity compensation activity rather than open-market trading. On February 24, 2026, restricted stock units vested and were converted into common stock, with blocks of 4,625 shares each delivered. In connection with these vestings, 1,358 shares were withheld in two separate transactions at fair market values of $38.09 and $38.25 per share to cover tax obligations. Following these transactions, Anthony continued to hold common stock directly.
Vericel Corp Chief Operating Officer Michael Halpin reported equity compensation activity involving Restricted Stock Units (RSUs) and common stock on February 24, 2026. RSU vesting led to multiple exercises (coded “M”), each for 5,250 units or shares at a price of $0.00 per share, increasing his direct holdings in both RSUs and common stock.
The filing shows common shares withheld in two “F”-coded transactions for 2,486 shares each, at fair market values of $38.09 and $38.25 per share, to satisfy tax withholding obligations. After these transactions, Halpin directly held 26,385 shares of Vericel common stock, along with RSU awards that continue to vest annually through February 2029.
Vericel Corp Chief Legal Officer Sean C. Flynn reported equity award activity on February 24, 2026. He acquired 3,500 and 3,000 shares of common stock through the vesting and conversion of Restricted Stock Units (RSUs) granted in 2025 and 2024, respectively. A total of 1,553 and 1,331 shares of common stock were withheld by Vericel at fair market values of $38.09 and $38.25 per share to cover tax obligations tied to these vestings. After these transactions, Flynn directly owned 7,683 shares of Vericel common stock.
Vericel Corp President and CEO Dominick Colangelo reported multiple equity transactions. On February 19, 2026, he was granted 182,500 stock options and 73,000 restricted stock units (RSUs), both at a stated price of $0 per unit, as part of his compensation.
Footnotes state the options begin vesting on February 19, 2026 and then in equal quarterly installments over four years, while the RSUs vest annually from February 19, 2027 through February 19, 2030. On February 18, 2026, earlier RSUs vested and converted into common stock, and 5,657 shares were withheld at $37.41 per share to cover tax obligations.
Vericel Corp Chief Legal Officer Sean C. Flynn reported multiple equity compensation transactions involving stock options, restricted stock units (RSUs), and common shares. On February 19, 2026, he was granted 35,000 stock options at an exercise price of $0.00 per share and 14,000 RSUs, both held directly. The options begin vesting on February 19, 2026 in equal quarterly installments over four years, while the RSUs vest annually from February 19, 2027 through February 19, 2030.
On February 18, 2026, common shares were acquired upon vesting of RSUs granted on February 18, 2022 and February 17, 2023, with each RSU representing one Vericel common share. In connection with this vesting, 1,490 shares at $36.82 and 1,030 shares at $37.41 were withheld by Vericel to satisfy tax withholding obligations, leaving 4,067 common shares held directly following the last reported transaction.
Vericel Corp Chief Medical Officer Jonathan Mark Hopper reported several equity-related transactions. He received a grant of 35,000 stock options and 14,000 restricted stock units (RSUs) on February 19, 2026, both at no cash cost to him.
On February 18, 2026, previously granted RSUs vested, converting into 3,000 and 2,325 shares of common stock. Of these, 3,000 shares were deferred into phantom stock units under Vericel’s Deferred Compensation Plan, payable later in common shares. The company withheld 982 shares of common stock at a fair market value of $37.41 per share to satisfy tax obligations related to the vesting.
Vericel Corp Chief Financial Officer Mara Joseph Anthony Jr reported several equity-related transactions. On February 19, 2026, he received grants of 46,250 stock options and 18,500 restricted stock units (RSUs), both at a price of $0.00 per share as compensation awards.
On February 18, 2026, RSUs granted in 2022 and 2023 vested, resulting in acquisitions of common stock through derivative exercises and conversions. In connection with these vestings, 1,505 and 809 shares of common stock were disposed of to cover tax withholding obligations at fair market values of $36.82 and $37.41 per share, respectively.
Vericel Corp principal accounting officer Jonathan Siegal reported several equity compensation transactions. On February 19, 2026, he received a grant of 6,600 stock options, which begin vesting on February 19, 2026 in equal quarterly installments over four years, and 6,160 restricted stock units (RSUs), which vest in four annual installments starting February 19, 2027 through 2030.
On February 18, 2026, RSUs previously granted in 2022 and 2023 vested, resulting in the acquisition of 2,500 and 420 shares of common stock, respectively. To cover tax withholding on these vestings, 1,117 shares at a fair market value of $36.82 per share and 188 shares at $37.41 per share were disposed of back to the issuer. Following these transactions, Siegal directly held 3,797 shares of Vericel common stock.
Vericel Corporation’s Chief Operating Officer Michael Halpin reported equity compensation and related share movements. On February 19, 2026, he was granted stock options for 52,500 shares and 21,000 Restricted Stock Units (RSUs), all held directly. These options begin vesting on February 19, 2026 in equal quarterly installments over four years, while the RSUs vest annually from February 19, 2027 through February 19, 2030.
On February 18, 2026, RSUs granted in 2022 and 2023 vested, converting into common stock. In connection with these vestings, the company withheld 2,486 shares at a fair market value of $36.82 per share and 1,812 shares at $37.41 per share to cover tax obligations. These transactions reflect compensation vesting and tax withholding rather than open-market buying or selling.
Vericel director Kevin F. McLaughlin reported an option exercise and share sale. On February 11, 2026, he exercised 7,000 stock options with a $2.63 exercise price, receiving 7,000 shares of common stock and bringing his direct holdings to 22,100 shares.
That same day, he sold 7,000 common shares in an open-market transaction at $34.66 per share under a pre-established Rule 10b5-1 trading plan, leaving him with 15,100 directly owned shares. Following the exercise, he also held 3,500 stock options at a $2.63 exercise price expiring on May 3, 2027, from an original grant covering 17,500 shares.
Vericel Corp’s Chief Operating Officer Michael Halpin reported option exercises and share sales. On 01/07/2026 he exercised 10,000 stock options at $16.66 per share, receiving 10,000 shares of common stock. He then sold 10,000 common shares at $40.48 per share in an automatic transaction under a Rule 10b5-1 trading plan adopted on November 19, 2024.
After these transactions, Halpin directly owned 16,080 shares of Vericel common stock and 46,250 stock options. The reported options were originally part of a grant representing the right to purchase 76,250 shares that vested in equal quarterly installments starting on May 6, 2019, contingent on continued service to the company.
Vericel Corporation’s chief human resources officer reported the vesting of equity awards on July 22, 2025. Restricted stock units granted on July 22, 2024 converted into 2,625 shares of common stock, with the issuer withholding 771 shares to satisfy tax obligations at a fair market value of $37.98 per share. After these transactions, the officer directly owns 1,854 common shares and 7,875 restricted stock units, each RSU representing the right to receive one Vericel share. The remaining RSUs from this grant are scheduled to vest in annual installments on July 22, 2026, July 22, 2027, and July 22, 2028.
Vericel (VCEL) reported an insider transaction by Chief Operating Officer Michael Halpin on 11/11/2025. He exercised a stock option for 2,642 shares at $16.66 (code M) and sold 2,642 shares at $40.41 (code S). The sale was executed automatically under a Rule 10b5-1 trading plan adopted on November 19, 2024.
Following the transactions, he directly owned 15,932 shares. Derivative holdings included 56,250 stock options. The footnotes note prior shares acquired under the 2015 Employee Stock Purchase Plan and the vesting schedule of the option grant.
Vericel (VCEL) reported an insider transaction by a director on 11/10/2025. The director exercised 7,000 stock options at an exercise price of $2.63 (code M) and sold 7,000 shares at an average price of $38.59 (code S) under a Rule 10b5-1 trading plan adopted on March 11, 2024.
Following these transactions, the director reported 15,100 shares beneficially owned directly and 10,500 options remaining beneficially owned. The options exercised were part of a grant from May 3, 2017 that vested in equal monthly installments over one year contingent on continued service.
Vericel (VCEL) reported an insider transaction by Chief Operating Officer Michael Halpin. On 11/06/2025, he exercised 7,358 stock options at $16.66 per share and sold 7,358 common shares at $40.47, with the sale executed under a Rule 10b5-1 trading plan adopted on November 19, 2024.
Following the transactions, Halpin directly beneficially owned 15,932 common shares. His remaining derivative holdings included 58,892 stock options. Footnotes note prior shares acquired under the company’s 2015 Employee Stock Purchase Plan.
Jonathan Siegal, Principal Accounting Officer of Vericel Corporation (VCEL), reported securities transactions dated 09/30/2025. He received 938 shares upon vesting of restricted stock units originally granted on 09/30/2021, with a stated fair market value of $31.47 per share. To satisfy tax withholding on the vesting, 370 shares were withheld by the issuer at that same $31.47 value. The filing shows 2,440 shares beneficially owned after the RSU vesting and 2,070 shares beneficially owned following the withholding transaction. The report was signed by an attorney-in-fact on behalf of Mr. Siegal on 10/02/2025.